EV-Based Gene Therapy Delivers Full-Length Dystrophin mRNA, Restores Muscle in DMD Models

A new treatment platform developed by researchers at The University of Texas MD Anderson Cancer Center delivered messenger RNA (mRNA) of the full-length DMD gene into preclinical models of Duchenne muscular dystrophy, successfully restoring the production of the muscle protein dystrophin and dramatically improving muscle strength, endurance and function in vivo. The study, published June 11, 2026, in Nature Biomedical Engineering, uses engineered extracellular vesicles (EVs) — natural nanoscale delivery particles — to carry the entire DMD gene, offering distinct benefits over current viral-based gene therapies, including reduced side effects and the ability to transfer the full-length gene.

Duchenne muscular dystrophy is a severe genetic disorder caused by mutations in the DMD gene that prevent the body from producing dystrophin, which helps stabilize and protect muscle cells during contractions in healthy individuals. Without dystrophin, muscles become easily damaged, leading to inflammation and cell death. The disease primarily affects males, with symptoms such as delayed walking and waddling usually appearing in early childhood, and as it progresses it leads to loss of walking ability, scoliosis, heart problems and eventual respiratory failure. Because DMD is the longest known gene in the human genome, current viral-based gene therapies are unable to carry the full length and must use shortened versions, resulting in loss of the gene's full function and carrying risks of serious side effects, dose-limiting toxicities, immune reactions and even possible death. These side effects have resulted in the removal of at least one Food and Drug Administration-approved gene therapy from the market.

In this study, the researchers loaded full-length DMD mRNA into EVs engineered with special tags that directly target and bind to skeletal muscles after being injected into the bloodstream. The muscle-targeting capability stems from the conjugation of specific ligands on the EV membrane that interact with receptors predominantly expressed on muscle tissue, improving biodistribution and minimizing sequestration by non-target organs. Injection of these mRNA-loaded EVs led to an increase in dystrophin protein expression as well as improved muscle strength and function in preclinical models, with no serious side effects. Muscle function and histopathology analyses showed marked improvement compared to controls, with reduced inflammation and muscle necrosis. The treatment stayed on target inside skeletal muscles and did not trigger any immune responses or toxicities commonly seen with viral-based treatments, even after repeated dosage. The work also demonstrated the safety and biocompatibility of the EVs in non-human primates, supporting their translational potential.

The non-viral nature of the delivery system sidesteps the immunogenicity issues associated with viral vectors. Unlike gene editing or viral gene replacement, mRNA therapy is transient and does not integrate into the host genome, mitigating risks of insertional mutagenesis and uncontrolled gene expression, which makes repeated dosing feasible. The formulated EVs exhibited exceptional stability in circulation, protecting the fragile mRNA cargo from enzymatic degradation, and the restoration of dystrophin protein reinstates the dystrophin-associated glycoprotein complex, which fortifies muscle cell membranes during mechanical stress.

mRNA technology, which was recognized by the 2023 Nobel Prize in Physiology or Medicine, has previously been used by the researchers to load EVs for enhancing responses to immunotherapy in glioblastoma, suggesting the technology's potential use for cancer therapy. The study's co-lead investigator stated, "Our new platform overcomes the limitations of current viral-based gene therapies, allowing for the delivery of full-length mRNA, restoring wild-type translation of dystrophin and significantly improving muscle function." Future studies are needed to determine the full safety of EV-mediated mRNA platforms for clinical trials, including whether they can be delivered to cardiac muscles, as heart conditions are commonly seen in advanced disease. Based on these results, the authors point out this could be a promising method beyond treating Duchenne muscular dystrophy, potentially serving as a broader "protein restoration" or cellular reprogramming platform. As the co-lead investigator noted, "Given that we are now able to replace very large proteins, this platform- and disease-agnostic approach could potentially open doors far beyond rare genetic disorders and traditional gene therapy applications," potentially enabling restoration of proteins lost through inherited diseases as well as acquired or degenerative processes, including cancer, autoimmune disorders, neurodegeneration, fibrosis and other chronic diseases.